NEW YORK (TheStreet) -- NuVasive (NUVA) - Get Report stock was upgraded to "equal weight" from "overweight" at Barclays on Friday morning. The firm set a $63 price target on the stock, up from its previous $58 price target.

Barclays raised its rating on NuVasive as it believes the medical device company's business is performing well and its acquisition of privately held medical technology company Eclipse will drive growth.

"It has been ~3 quarters since the launch of NUVA's iGA platform, and our survey shows this as an incremental positive for NUVA," Barclays said in a note.

"Further, given the acquisition of its Brazilian distributor, stability outside the U.S. (OUS), and launch of Attrax, we think NUVA is set up for strong top-line growth and can beat conservative guidance in 2016 and numbers in 2017-18," the firm added.

Shares of NuVasive are up by 1.44% to $54.09 at the start of trading on Friday morning.

Separately, TheStreet Ratings has set a "hold" rating and a score of C on NuVasive stock.  The primary factors that have impacted the rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.

The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, TheStreet Ratings also finds weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: NUVA

Image placeholder title